<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene G142D;E154K;L452R;E484Q;D614G;P681R;Q1071H;H1101D literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.G142D;E154K;L452R;E484Q;D614G;P681R;Q1071H;H1101D</span> literature reference collection</h1>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Neutralization efficiency (ID50) against B.1.617.1-v1 ("Kappa") reduced 3.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.<br/> (<a href="https://doi.org/10.1101/2021.06.28.449914" class="lit_link">Choi et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> In a cluster of B.1.617[.1] infections related to travel from India to USA, one patient with mild symptoms had received their second dose of Pfizer vaccine more than two weeks before the infection [i.e. vaccine breakthrough].<br/> (<a href="https://doi.org/10.1128/JCM.00741-21" class="lit_link">Verghese et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
